Spyre Therapeutics Inc reports results for the quarter ended September 30 - Earnings Summary

What happened

Spyre Therapeutics reported an adjusted loss of 94 cents per share for the quarter ended September 30, compared with a loss per share a year earlier. Revenue was zero, matching analyst expectations, while analysts had forecast an average loss of 83 cents per share.

Confirmed

Global impact / market context

The company reported no revenue and a quarterly loss of $96.12 million, so investors will focus on how it funds operations and whether future progress can eventually produce sales. The larger per-share loss than analysts expected may weigh on expectations, although the article gives no market reaction to the results.

Analyst inference

Analysts’ average earnings estimate had fallen about 8.1% over three months, and one analyst cut an estimate in the past 30 days. The shares had gained 191.5% year to date, while the average analyst rating remained “buy.”

Confirmed

What to watch

1. Watch for future revenue and loss updates: revenue was zero this quarter, and continued losses without sales could increase the importance of funding and cost control. Analyst inference
2. Track whether analyst earnings estimates continue to fall or stabilize; estimates are analysts’ forecasts, and further cuts could signal weaker expected results. Analyst inference
3. The article reports a $123 median 12-month analyst price target, about 22.3% above the $95.51 last closing price; compare later results with that forecast. Confirmed

Evidence

• Original source link unavailable